Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
Anticancer Research · 2026-08 · 46 (8) · 4453-4460
DOI: 10.21873/anticanres.18301 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Yuki Kobari und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; yuukikobari17@gmail.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; yuukikobari17@gmail.com.
- Department of Urology, Tokyo Women's Medical University, Adachi Medical Center, Tokyo, Japan.
- Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan.
- Department of Urology, Saiseikai Kazo Hospital, Kazo, Japan.
- Department of Urology, Todachuo General Hospital, Toda, Japan.
- Department of Urology, Joban Hospital, Iwaki, Japan.
Zitieren
APA
Kobari, Y., Nakajima, N., Saito, A., Katsurayama, N., Inakawa, T., Kubota, S., Nemoto, Y., Nakamura, K., Nishimura, K., Ishihara, H., Yagisawa, T., Fukuda, H., Yoshida, K., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., Kobayashi, H., & Takagi, T. (2026). Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer Research, 46(8), 4453-4460. https://doi.org/10.21873/anticanres.18301
Vancouver
Kobari Y, Nakajima N, Saito A, Katsurayama N, Inakawa T, Kubota S, et al. Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer Research. 2026;46(8):4453-4460. doi:10.21873/anticanres.18301
BibTeX
@article{Kobari2026,
author = {Kobari, Yuki and Nakajima, Nao and Saito, Akira and Katsurayama, Nanaka and Inakawa, Toru and Kubota, Satoshi and Nemoto, Yuki and Nakamura, Kazutaka and Nishimura, Kouichi and Ishihara, Hiroki and Yagisawa, Takafumi and Fukuda, Hironori and Yoshida, Kazuhiko and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Kobayashi, Hiroshi and Takagi, Toshio},
title = {Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4453--4460},
doi = {10.21873/anticanres.18301}
}
EUVIMED